While these treatments remain the best available for the DMD patients of today, these ASO treatments require lifetime weekly intravenous infusions,34,35,36,37 restore low levels of dystrophin protein (<6%), and were initially approved based on the findings of low levels of dystrophin restoration rather than functional benefit.17 The gene discussed is DMD; the disease is Duchenne muscular dystrophy.